A New Approach to Control the Enigmatic Activity of Aldose Reductase

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Del Corso, Antonella ^a   Balestri, Francesco ^a   Di Bugno, Elisa ^a   Moschini, Roberta ^a   Cappiello, Mario ^a   Sartini, Stefania ^a   La Motta, Concettina ^a   Da Settimo, Federico ^a   Mura, Umberto ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 GLUTATHIONYL 4 HYDROXY NONANAL; 4 HYDROXYNONENAL; ALDEHYDE REDUCTASE; GLUCOSE; GLYCERALDEHYDE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME SUBSTRATE; GLUCOSE METABOLISM; GLUCOSE REDUCTION; IN VITRO STUDY;

ALDEHYDE REDUCTASE; ALDEHYDES; DIABETES COMPLICATIONS; GLUCOSE; GLYCERALDEHYDE; SUBSTRATE SPECIFICITY;

EID: 84883393829     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074076     Document Type: Article

References (62)

1. Del Corso A, Costantino L, Rastelli G, Buono F, Mura U, (2000) Aldose reductase does catalyse the reduction of glyceraldehyde through a stoichiometric oxidation of NADPH. Exp Eye Res 71: 515-521. doi:10.1006/exer.2000.0906. PubMed: 11040087.
2. Del Corso A, Cappiello M, Mura U, (2008) From a dull enzyme to something else: facts and perspectives regarding aldose reductase. Curr Med Chem 15: 1452-1461. doi:10.2174/092986708784638870. PubMed: 18537622.
3. Tang WH, Martin KA, Hwa J, (2012) Aldose reductase, oxidative stress, and diabetic mellitus Front. Pharmacologist. doi:10.3389/fphar.2012.00087.
4. Hers HG, (1956) The mechanism of the transformation of glucose in fructose in the seminal vesicles. Biochim Biophys Acta 22: 202-203. doi:10.1016/0006-3002(56)90247-5. PubMed: 13373872.
5. Kinoshita JH, (1974) Mechanisms initiating cataract formation. Proctor Lecture. Invest Ophthalmol Vis Sci 13: 713-724.
6. Lee AY, Chung SS, (1999) Contributions of polyol pathway to oxidative stress in diabetic cataract. FASEB J 13: 23-30. PubMed: 9872926.
7. El-Kabbani O, Ruiz F, Darmanin C, Chung RP, (2004) Aldose reductase structures: implications for mechanism and inhibition. Cell Mol Life Sci 61: 750-762. doi:10.1007/s00018-003-3403-2. PubMed: 15095000.
8. Hamada Y, Araki N, Koh N, Nakamura J, Horiuchi S, et al. (1996) Rapid formation of advanced glycation end products by intermediate metabolites of glycolytic pathway and polyol pathway. Biochem Biophys Res Commun 228: 539-543. doi:10.1006/bbrc.1996.1695. PubMed: 8920948.
9. Stevens VJ, Vlassara H, Abati A, Cerami A, (1977) Nonenzymatic glycosylation of hemoglobin. J Biol Chem 252: 2998-3002. PubMed: 856810.
10. Alexiou P, Pegklidou K, Chatzopoulou M, Nicolaou I, Demopoulos VJ, (2009) Aldose reductase enzyme and its implication to major health problems of the 21(st) century. Curr Med Chem 16: 734-752. doi:10.2174/092986709787458362. PubMed: 19199934.
11. Bresson E, Lacroix-Péppin N, Boucher-Kovalik S, Chapdelaine P, Fortier MA, (2012) The prostaglandin F synthase activity of the human aldose reductase AKR1B1 brings new lenses to look at pathologic conditions. Front Pharmacol. doi:10.3389/fphar.2012.00098.
12. Pandey S, Srivastava SK, Ramana KV, (2012) A potential therapeutic role for aldose reductase inhibitors in the treatment of endotoxin-related inflammatory diseases. Expert Opin Investig Drugs 21: 329-339. doi:10.1517/13543784.2012.656198. PubMed: 22283786.
13. Laffin B, Petrash JM, (2012) Expression of the aldo-ketoreductases AKR1B1 and AKR1B10 in human cancers. Front Pharmacol. doi:10.3389/fphar.2012.00104.
14. Ramana KV, Srivastava SK, (2010) Aldose reductase: a novel therapeutic target for inflammatory pathologies. Int J Biochem Cell Biol 42: 17-20. doi:10.1016/j.biocel.2009.09.009. PubMed: 19778627.
15. Chung SS, Chung SK, (2005) Aldose reductase in diabetic microvascular complications. Curr Drug Targ 6: 475-486. doi:10.2174/1389450054021891. PubMed: 16026266.
16. Greene DA, Sima AA, Stevens MJ, Feldman EL, Killen PD, et al. (1993) Aldose reductase inhibitors: an approach to the treatment of diabetic nerve damage. Diabetes Metab Rev 9: 189-217. doi:10.1002/dmr.5610090304. PubMed: 8187607.
17. Cappiello M, Vilardo PG, Cecconi I, Leverenz V, Giblin FJ, et al. (1995) Occurrence of glutathione-modified aldose reductase in oxidatively stressed bovine lens. Biochem Biophys Res Commun 207: 775-782. doi:10.1006/bbrc.1995.1254. PubMed: 7864872.
18. Cappiello M, Vilardo PG, Micheli V, Jacomelli G, Banditelli S, et al. (2000) Thiol disulfide exchange modulates the activity of aldose reductase in intact bovine lens as a response to oxidative stress. Exp Eye Res 70: 795-803. doi:10.1006/exer.2000.0838. PubMed: 10843784.
19. Endo S, Fujimoto A, Kumada S, Matsunaga T, Ohno S, et al. (2013) Modulation of activity and inhibitor sensitivity of rabbit aldose reductase-like protein (AKR1B19) by oxidized glutathione and SH-reagents. Chem Biol Interact 202: 146-152. doi:10.1016/j.cbi.2012.11.026. PubMed: 23261715.
20. Shen Y, Zhong L, Markwell S, Cao D, (2010) Thiol-disulfide exchanges modulate aldoketo reductase family 1 member B10 activity and sensitivity to inhibitors. Biochimie 92: 530-537. doi:10.1016/j.biochi.2010.02.001. PubMed: 20144905.
21. Krans HM, (1993) Recent clinical experience with aldose reductase inhibitors. Diabet Med 10: S44-S48. doi:10.1111/j.1464-5491.1993.tb00198.x. PubMed: 83348421562757.
22. Foppiano M, Lombardo G, (1997) Worldwide pharmacovigilance systems and tolrestat withdrawal. Lancet 349: 399-400. doi:10.1016/S0140-6736(97)80018-9. PubMed: 9033472.
23. Esterbauer H, Schaur RJ, Zollner H, (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81-128. doi:10.1016/0891-5849(91)90192-6. PubMed: 1937131.
24. Srivastava S, Chandra A, Bhatnagar A, Srivastava SK, Ansari NH, (1995) Lipid peroxidation product, 4-hydroxynonenal and its conjugate with GSH are excellent substrates of bovine lens aldose reductase. Biochem Biophys Res Commun 217: 741-746. doi:10.1006/bbrc.1995.2835. PubMed: 8554593.
25. Ramana KV, Fadl AA, Tammali R, Reddy AB, Chopra AK, et al. (2006) Aldose reductase mediates the lipopolysaccharide-induced release of inflammatory mediators in RAW264.7 murine macrophages. J Biol Chem 281: 33019-33029.
26. Burg MB, (1995) Molecular basis of osmotic regulation. Am J Physiol 268: F983-F996. PubMed: 7611465.
27. Steffgen J, Kampfer K, Grupp C, Langenberg C, Müller GA, et al. (2003) Osmoregulation of aldose reductase and sorbitol dehydrogenase in cultivated interstitial cells of rat renal inner medulla. Nephrol Dial Transplant 18: 2255-2261. PubMed: 14551351.
28. Hirakawa H, Sawada H, Yamahama Y, Takikawa S, Shintaku H, et al. (2009) Expression analysis of the aldo-keto reductases involved in the novel biosynthetic pathway of tetrahydrobiopterin in human and mouse tissues. J Biochem 146: 51-60. PubMed: 19273550.
29. Park YS, Heizmann CW, Wermuth B, Levine RA, Steinerstauch P, et al. (1991) Human carbonyl and aldose reductases: new catalytic functions in tetrahydrobiopterin biosynthesis. Biochem Biophys Res Commun 175: 738-744. PubMed: 1902669.
30. Wermuth B, Monder C, (1983) Aldose and aldehyde reductase exhibit isocorticosteroid reductase activity. Eur J Biochem 131: 423-426. PubMed: 6403351.
31. Petrash JM, Harter TM, Murdock GL, (1997) A potential role for aldose reductase in steroid metabolism. Adv Exp Med Biol 414: 465-473. PubMed: 9059652.
32. Endo S, Matsunaga T, Mamiya H, Ohta C, Soda M, et al. (2009) Kinetic studies of AKR1B10, human aldose reductase-like protein: endogenous substrates and inhibition by steroids. Arch Biochem Biophys 487: 1-9. PubMed: 19464995.
33. Cappiello M, Voltarelli M, Giannessi M, Cecconi I, Camici G, et al. (1994) Glutathione dependent modification of bovine lens aldose reductase. Exp Eye Res 58: 491-501. PubMed: 7925685.
34. Srivastava S, Watowich SJ, Petrash JM, Srivastava SK, Bhatnagar A, (1999) Structural and kinetic determinants of aldehyde reduction by aldose reductase. Biochemistry 38: 42-54. PubMed: 9890881.
35. Vander Jagt DL, Kolb NS, Vander Jagt TJ, Chino J, Martinez FJ, et al. (1995) Substrate specificity of human aldose reductase: identification of 4-hydroxynonenal as an endogenous substrate. Biochim Biophys Acta 1249: 117-126. PubMed: 7599164.
36. Grimshaw CE, (1992) Aldose reductase: model for a new paradigm of enzymic perfection in detoxification catalysts. Biochemistry 31: 10139-10145. PubMed: 1420136.
37. Srivastava SK, Ramana KV, Bhatnagar A, (2005) Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. Endocr Rev 26: 380-392. PubMed: 15814847.
38. Kumar H, Shah A, Sobhia ME, (2012) Novel insights into the structural requirements for the design of selective and specific aldose reductase inhibitors. J Mol Model 18: 1791-1799. PubMed: 21833829.
39. Costantino L, Rastelli G, Vescovini K, Cignarella G, Vianello P, et al. (1996) Synthesis, activity and molecular modeling of a new series of tricyclic pyridazinones as selective aldose reductase inhibitors. J Med Chem 39: 4396-4405. PubMed: 8893834.
40. La Motta C, Sartini S, Mugnaini L, Simorini F, Taliani S, et al. (2007) Pyrido[1,2-a]pyrimidin-4-one derivatives as a novel class of selective aldose reductase inhibitors exhibiting antioxidant activity. J Med Chem 50: 4917-4927.
41. La Motta C, Sartini S, Salerno S, Simorini F, Taliani S, et al. (2008) Acetic acid aldose reductase inhibitors bearing a five-membered heterocyclic core with potent topical activity in a visual impairment rat model. J Med Chem 51: 3182-3193. PubMed: 18452283.
42. Da Settimo F, Primofiore G, La Motta C, Sartini S, Taliani S, et al. (2005). Naphtho[1,2-d]isothiazole acetic acid derivatives as a novel class of selective aldose reductase inhibitors. J Med Chem 48: 6897-6907.
43. Da Settimo F, Primofiore G, Da Settimo A, La Motta C, Taliani S, et al. (2001) 1,2,4]Triazino[4,3-a]benzimidazole acetic acid derivatives: a new class of selective aldose reductase inhibitors. J Med Chem 44: 4359-4369.
44. Da Settimo A, Primofiore G, La Motta C, Da Settimo F, Simorini F, et al. (1996) Acid derivatives of benzisothiazole-1,1-dioxide as inhibitors of rat lens aldose reductase. Farm 51: 261-267.
45. Primofiore G, Da Settimo F, La Motta C, Simorini F, Minutolo A, et al. (1997) Benzisothiazole-1,1-dioxide alkanoic acid derivatives as inhibitors of rat lens aldose reductase. Il Farmaco 52: 583-588.
46. Del Corso A, Barsacchi D, Giannessi M, Tozzi MG, Camici M, et al. (1990) Bovine lens aldose reductase: tight binding of the pyridine coenzyme. Arch Biochem Biophys 283: 512-518. PubMed: 2125822.
47. Gérard-Monnier D, Erdelmeier I, Régnard K, Moze-Henry N, Yadan JC, et al. (1998) Reactions of 1-methyl-2-phenylindole with malondialdehyde and 4-hydroxyalkenals. Analytical applications to a colorimetric assay of lipid peroxidation. Chem Res Toxicol 11: 1176-1183.
48. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254. PubMed: 942051.
49. Hayman S, Kinoshita JH, (1965) Isolation and properties of lens aldose reductase. J Biol Chem 240: 77-882. PubMed: 14275148.
50. Petrash JM, Harter TM, Devine CS, Olins PO, Bhatnagar A, et al. (1992) Involvement of cysteine residues in catalysis and inhibition of human aldose reductase. Site-directed mutagenesis of Cys-80,-298, and-303. J Biol Chem 267: 24833-24840.
51. Ramana KV, Dixit BL, Srivastava S, Balendiran GK, Srivastava SK, et al. (2000) Selective recognition of glutathiolated aldehydes by aldose reductase. Biochemistry 39: 12172-12180. PubMed: 11015195.
52. Srivastava S, Chandra A, Ansari NH, Srivastava SK, Bhatnagar A, (1998) Identification of cardiac oxidoreductase(s) involved in the metabolism of the lipid peroxidation-derived aldehyde-4-hydroxynonenal. Biochem J 329: 469-475. PubMed: 9445372.
53. Vander Jagt DL, Robinson B, Taylor KK, Hunsaker LA, (1992) Reduction of trioses by NADPH-dependent aldo-keto reductases. Aldose reductase, methylglyoxal, and diabetic complications. J Biol Chem 267: 4364-4369. PubMed: 1537826.
54. Del Corso A, Dal Monte M, Vilardo PG, Cecconi I, Moschini R, et al. (1998) Site-specific inactivation of aldose reductase by 4-hydroxynonenal. Arch Biochem Biophys 350: 245-248. PubMed: 9473298.
55. Selwyn MJ, (1965) A simple test for inactivation of an enzyme during the assay. Biochim Biophys Acta 105: 193-195. PubMed: 4221326.
56. Bhatnagar A, Liu SQ, Ueno N, Chakrabarti B, Srivastava SK, (1994) Human placental aldose reductase: role of Cys-298 in substrate and inhibitor binding. Biochim Biophys Acta 1205: 207-214. PubMed: 8155699.
57. Gabbay KH, Tze WJ, (1972) Inhibition of glucose-induced release of insulin by aldose reductase inhibitors. Proc Natl Acad Sci U S A 69: 1435-1439. PubMed: 4402538.
58. Vander Jagt DL, Hunsaker LA, Robinson B, Stangebye LA, Deck LM, (1990) Aldehyde and aldose reductases from human placenta. Heterogeneous expression of multiple enzyme forms. J Biol Chem 265: 10912-10918. PubMed: 2113526.
59. Inoue J, Cui YS, Sakai O, Nakamura Y, Kogiso H, et al. (2000) Synthesis and aldose reductase inhibitory activities of novel N-nitromethylsulfonanilide derivatives. Bioorg Med Chem 8: 2167-2173. PubMed: 11003161.
60. Kim TH, Kim JK, Kang YH, Lee JY, Kang IJ, et al. (2013) Aldose reductase inhibitory activity of compounds from Zea mays L. Biomed Res Int,(2013): pp. 727143. doi:10.1155/2013/727143. PubMed: 23586057. PubMed: 23586057.
61. Ottanà R, Maccari R, Giglio M, Del Corso A, Cappiello M, et al. (2011) Identification of 5-arylidene-4-thiazolidinone derivatives endowed with dual activity as aldose reductase inhibitors and antioxidant agents for the treatment of diabetic complications. Eur J Med Chem 46: 2797-2806.
62. Zheng X, Zhang L, Zhai J, Chen Y, Luo H, et al. (2012) The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase. FEBS Lett 586: 55-59. PubMed: 22155003.